Literature DB >> 14536078

Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation.

Markus Welcker1, Jeffrey Singer, Keith R Loeb, Jonathan Grim, Andrew Bloecher, Mark Gurien-West, Bruce E Clurman, James M Roberts.   

Abstract

Autophosphorylation-triggered ubiquitination has been proposed to be the major pathway regulating cyclin E protein abundance: phosphorylation of cyclin E on T380 by its associated CDK allows binding to the receptor subunit, Fbw7, of the SCFFbw7 ubiquitin ligase. We have tested this model in vivo and found it to be an inadequate representation of the pathways that regulate cyclin E degradation. We show that assembly of cyclin E into cyclin E-Cdk2 complexes is required in vivo for turnover by the Fbw7 pathway; that Cdk2 activity is required for cyclin E turnover in vivo because it phosphorylates S384; that phosphorylation of T380 in vivo does not require Cdk2 and is mediated primarily by GSK3; and that two additional phosphorylation sites, T62 and S372, are also required for turnover. Thus, cyclin E turnover is controlled by multiple biological inputs and cannot be understood in terms of autophosphorylation alone.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14536078     DOI: 10.1016/s1097-2765(03)00287-9

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  164 in total

1.  Composite low affinity interactions dictate recognition of the cyclin-dependent kinase inhibitor Sic1 by the SCFCdc4 ubiquitin ligase.

Authors:  Xiaojing Tang; Stephen Orlicky; Tanja Mittag; Veronika Csizmok; Tony Pawson; Julie D Forman-Kay; Frank Sicheri; Mike Tyers
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-10       Impact factor: 11.205

2.  The glomuvenous malformation protein Glomulin binds Rbx1 and regulates cullin RING ligase-mediated turnover of Fbw7.

Authors:  Adriana E Tron; Takehiro Arai; David M Duda; Hiroshi Kuwabara; Jennifer L Olszewski; Yuko Fujiwara; Brittany N Bahamon; Sabina Signoretti; Brenda A Schulman; James A DeCaprio
Journal:  Mol Cell       Date:  2012-03-08       Impact factor: 17.970

3.  Nonessential sites improve phosphorylation switch.

Authors:  Liming Wang; Qing Nie; German Enciso
Journal:  Biophys J       Date:  2010-09-22       Impact factor: 4.033

Review 4.  GSK3 signalling in neural development.

Authors:  Eun-Mi Hur; Feng-Quan Zhou
Journal:  Nat Rev Neurosci       Date:  2010-08       Impact factor: 34.870

Review 5.  Ubiquitin, the centrosome, and chromosome segregation.

Authors:  Ying Zhang; Paul J Galardy
Journal:  Chromosome Res       Date:  2016-01       Impact factor: 5.239

Review 6.  Design Principles Involving Protein Disorder Facilitate Specific Substrate Selection and Degradation by the Ubiquitin-Proteasome System.

Authors:  Mainak Guharoy; Pallab Bhowmick; Peter Tompa
Journal:  J Biol Chem       Date:  2016-02-05       Impact factor: 5.157

7.  Pan-cancer transcriptional signatures predictive of oncogenic mutations reveal that Fbw7 regulates cancer cell oxidative metabolism.

Authors:  Ryan J Davis; Mehmet Gönen; Daciana H Margineantu; Shlomo Handeli; Jherek Swanger; Pia Hoellerbauer; Patrick J Paddison; Haiwei Gu; Daniel Raftery; Jonathan E Grim; David M Hockenbery; Adam A Margolin; Bruce E Clurman
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-07       Impact factor: 11.205

Review 8.  GSK3beta: role in therapeutic landscape and development of modulators.

Authors:  S Phukan; V S Babu; A Kannoji; R Hariharan; V N Balaji
Journal:  Br J Pharmacol       Date:  2010-03-19       Impact factor: 8.739

9.  Differences in degradation lead to asynchronous expression of cyclin E1 and cyclin E2 in cancer cells.

Authors:  C Elizabeth Caldon; C Marcelo Sergio; Robert L Sutherland; Elizabeth A Musgrove
Journal:  Cell Cycle       Date:  2013-01-16       Impact factor: 4.534

10.  Inhibitory effects of fenofibrate on apoptosis and cell proliferation in human endothelial cells in high glucose.

Authors:  Michela Zanetti; Alessia Stocca; Barbara Dapas; Rossella Farra; Laura Uxa; Alessandra Bosutti; Rocco Barazzoni; Fleur Bossi; Carlo Giansante; Francesco Tedesco; Luigi Cattin; Gianfranco Guarnieri; Gabriele Grassi
Journal:  J Mol Med (Berl)       Date:  2007-09-18       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.